What is elamipretide? Learn how this mitochondria-targeted peptide (SS-31, MTP-131) works, what research shows, and its FDA status in the US.
Elamipretide is a synthetic tetrapeptide designed to concentrate inside mitochondria, the structures that produce most of a cell's energy. It works by binding to cardiolipin on the inner mitochondrial membrane, which researchers believe helps stabilize that membrane under oxidative stress. The compound is also known as SS-31, MTP-131, and Bendavia, and it remains an investigational drug rather than an approved therapy.
What Is Elamipretide and How Does It Work?
Elamipretide is a short chain of four amino acids (D-Arg-Dmt-Lys-Phe-NH2) with a chemical structure that gives it a mild positive charge. That charge draws the peptide toward the inner mitochondrial membrane, where cardiolipin sits.
The proposed mechanism is membrane protection, not energy production. By associating with cardiolipin, elamipretide may help preserve the membrane's shape and support the electron transport chain during periods of cellular stress.
Early animal and cell studies reported reduced reactive oxygen species and improved mitochondrial function. Human trial results have been more mixed, which is part of why no regulatory agency has cleared elamipretide peptide products for general use.
Elamipretide Peptide Names: SS-31, MTP-131, Bendavia, and Forzinity
Much of the confusion around this molecule comes from its many names. The table below maps each label to the context where it usually appears.
| Name | What it refers to | Where you usually see it |
|---|---|---|
| Elamipretide | The current generic name | Recent clinical literature and reviews |
| SS-31 | The original research code | Academic mechanism and animal studies |
| MTP-131 | A corporate development code | Industry-sponsored clinical trials |
| Bendavia | An older brand name | Early heart and kidney trials |
| Forzinity | A newer brand name | Regulatory filings for Barth syndrome |
If you see 'ss 31 elamipretide,' 'elamipretide ss-31,' or 'ss31 elamipretide,' all three point to the identical four-amino-acid sequence. The phrase 'elamipretide drug' also appears in news coverage, even though the molecule is still investigational rather than approved.
What Conditions Are Being Studied?
Elamipretide research focuses on conditions where mitochondria fail to meet the body's energy demands. None of these uses are approved outside of clinical trials.
Barth Syndrome and Primary Mitochondrial Myopathy
These are rare genetic conditions that directly affect mitochondrial function. Small trials reported improvements in some functional measures, but the results have not been consistent enough across studies to support regulatory approval.
Heart Failure and Kidney Injury
Researchers have tested elamipretide in heart failure with preserved ejection fraction and in cardiac surgery patients at risk of kidney injury. Endpoints such as exercise capacity and biomarker levels have produced mixed findings.
Other Areas Under Exploration
- Age-related vision loss and retinal oxidative stress
- Neurodegenerative conditions linked to mitochondrial damage
- Ischemia-reperfusion injury during surgery
Is Elamipretide FDA-Approved?
No. Elamipretide has not received FDA approval for any human indication, and it is not available by prescription in the United States.
The developer has pursued approval for Barth syndrome under the brand name Forzinity elamipretide, and the regulatory path has remained uncertain. Statements that present elamipretide as an approved or proven treatment are not supported by the current record.
Products sold online as research chemicals are not the same as an approved medicine. They are not verified for purity, dose accuracy, or sterility in the way pharmaceutical manufacturing is.
Dosing, Safety, and Side Effects in Research
In clinical trials, elamipretide has been given as a subcutaneous injection, and dosing has varied widely by condition. There is no established human dose, and self-dosing outside a supervised trial is not advisable.
Reported side effects in trials have generally been mild and include:
- Injection-site reactions such as redness or discomfort
- Headache
- Nausea
- Fatigue
These are trial observations, not a complete safety profile. Anyone considering a mitochondrial peptide should talk with a healthcare professional first, and the same caution applies to sourcing and handling questions people have when they look up what is bacteriostatic water for injection used for.
Elamipretide Compared With Other Research Peptides
Elamipretide is often discussed alongside other peptides even though their mechanisms differ. The table below compares the most common points of confusion.
| Compound | Primary research target | Typical route studied | FDA status |
|---|---|---|---|
| Elamipretide (SS-31) | Mitochondrial membrane cardiolipin | Subcutaneous injection | Not approved |
| BPC-157 | Tissue repair and angiogenesis | Injection or oral, research only | Not approved |
| IGF-1 LR3 | Growth signaling | Injection, research only | Not approved |
| KPV | Inflammation signaling | Topical or injection, research only | Not approved |
People who ask what is bpc-157 made of are usually working from a very different premise, since BPC-157 is a larger peptide derived from a gastric protein rather than a mitochondria-targeted tetrapeptide. In the same way, what is igf-1 lr3 used for leads toward growth hormone research, and what is kpv peptide used for leads toward a small anti-inflammatory tripeptide.
The search question 'What is the difference between KPV and BPC-157?' also comes up often, and neither compound shares elamipretide's cardiolipin-binding mechanism. Each peptide has its own evidence base, and the evidence base for elamipretide is still mostly early-stage.
Key Takeaways
- Elamipretide is a mitochondria-targeted tetrapeptide also known as SS-31, MTP-131, and Bendavia.
- Its proposed mechanism is cardiolipin binding and membrane stabilization, not direct energy production.
- Elamipretide is not FDA-approved, and human trial results have been mixed.
- Reported side effects in trials are mostly mild, but the long-term safety profile is not established.
- Unregulated research peptides are not equivalent to pharmaceutical-grade medicine.
Frequently Asked Questions
What is elamipretide used for?
Elamipretide is an investigational peptide studied for conditions tied to mitochondrial dysfunction, including Barth syndrome, primary mitochondrial myopathy, and heart failure with preserved ejection fraction. It is not approved to treat any of those conditions, and it is not a general wellness or anti-aging product. Any use outside a supervised clinical trial is unproven.
Is elamipretide FDA-approved?
No, elamipretide has not been approved by the FDA for any indication. The manufacturer has pursued approval for Barth syndrome under the brand name Forzinity, and that regulatory pathway has remained unresolved. Products sold as research chemicals are not FDA-approved drugs.
Is elamipretide the same as SS-31, MTP-131, or Bendavia?
Yes, they all refer to the same molecule. SS-31 was the original research code, MTP-131 was used during commercial development, and Bendavia and Forzinity are brand names. Elamipretide is the generic name used in current scientific literature.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.